Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | RPRX |
---|---|---|
09:32 ET | 42113 | 26.56 |
09:34 ET | 2340 | 26.505 |
09:36 ET | 2269 | 26.52 |
09:38 ET | 2100 | 26.495 |
09:39 ET | 3509 | 26.53 |
09:41 ET | 12809 | 26.485 |
09:43 ET | 9834 | 26.56 |
09:45 ET | 800 | 26.575 |
09:48 ET | 4912 | 26.4995 |
09:50 ET | 1549 | 26.5 |
09:52 ET | 4359 | 26.428 |
09:54 ET | 1900 | 26.404 |
09:56 ET | 1415 | 26.37 |
09:57 ET | 2221 | 26.385 |
09:59 ET | 10597 | 26.38 |
10:01 ET | 2629 | 26.375 |
10:03 ET | 27880 | 26.375 |
10:06 ET | 6791 | 26.41 |
10:08 ET | 9070 | 26.365 |
10:10 ET | 6513 | 26.325 |
10:12 ET | 6272 | 26.34 |
10:14 ET | 4925 | 26.325 |
10:15 ET | 5939 | 26.28 |
10:17 ET | 3821 | 26.27 |
10:19 ET | 3698 | 26.225 |
10:21 ET | 7473 | 26.265 |
10:24 ET | 8893 | 26.18 |
10:26 ET | 11359 | 26.15 |
10:28 ET | 5337 | 26.17 |
10:30 ET | 3223 | 26.18 |
10:32 ET | 4153 | 26.16 |
10:33 ET | 1500 | 26.135 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Royalty Pharma PLC | 15.9B | 14.7x | +1.83% |
Amneal Pharmaceuticals Inc | 2.1B | -12.0x | --- |
Catalent Inc | 9.8B | -8.3x | --- |
Jazz Pharmaceuticals PLC | 6.6B | 21.5x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Prestige Consumer Healthcare Inc | 3.2B | 15.0x | --- |
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $15.9B |
---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 597.4M |
Dividend Yield | 3.21% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 05-16-24 |
Pay Date | 06-14-24 |
Beta | 0.46 |
EPS | $1.78 |
Book Value | $14.61 |
P/E Ratio | 14.7x |
Price/Sales (TTM) | 7.1 |
Price/Cash Flow (TTM) | 13.4x |
Operating Margin | 41.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.